search
Back to results

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

Primary Purpose

Bipolar Disorder

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
MCN36 (nutritional supplement)
Placebo
Sponsored by
University of Calgary
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder focused on measuring bipolar disorder, mood disorders, manic depression, nutrition

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Must meet the criteria for bipolar disorder I or II as defined in DSM-IV-TR based on clinical assessment and confirmed by structured diagnostic interview (SCID-P). Must be symptomatic on the Hamilton Depression Scale and the Young Mania Rating Scale Must be free of medications or herbal/nutritional supplements with primarily central nervous system activity Must be able to eat at least a snack three times per day, so that the capsules will not be ingested on an empty stomach Exclusion Criteria: Current or lifetime diagnosis of any of the following according to DSM-IV-TR criteria: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Psychotic Disorder Not Otherwise Specified, Delirium of any type, Dementia of any type, Amnestic Disorder, unless there is substantive reason to believe the patient was misdiagnosed. Alcohol dependence or abuse in the previous six months. Dependence or abuse of substances other than alcohol in the previous two years. Any Psychotic Disorder due to a General Medical Condition in the previous two years Hospitalization for treatment of a mental disorder within the previous 6 months. Current use of any other medication or herbal/nutritional supplement with primarily central nervous system activity. Neurological disorder involving brain or other central function. Severe headaches of any type (including migraine) within the previous 3 months. Unstable illnesses either with active significant symptoms or requiring medication changes within the previous 4 months. Abnormal laboratory values detected at screening, in particular an ALT or AST greater than 2 times the upper limit of normal, or creatinine greater than 1.75 times the upper limit of normal. Uncorrected or unstable hypothyroidism or hyperthyroidism in the previous 12 months. Medically diagnosed Irritable Bowel Syndrome, or any other chronic gastrointestinal problem, within the previous 3 years. Current or lifetime metabolic disorder or problem, such as phenylketonuria or Wilson's disease. A course of treatment with electroconvulsive therapy (ECT) within the previous 12 months, or a lifetime history of four or more courses of ECT. Current bacterial, viral, fungal, parasite or other infection. Women who are pregnant or breast-feeding; women of childbearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse.

Sites / Locations

  • Dr Estelle Goldstein
  • University of Calgary Faculty of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

2

1

Arm Description

Placebo comparator, 6 placebo capsules three times a day

nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.

Outcomes

Primary Outcome Measures

Mood as Evaluated by the Overall Bipolarity Index (Composite of the Hamilton Depression Scale and the Young Mania Rating Scale)
Change in mood from baseline to final visit, as evaluated by the Overall Bipolarity Index (composite of the Hamilton Depression Scale and the Young Mania Rating Scale); minimum possible score is 0 and maximum possible score is 103; higher scores mean worse symptomatology

Secondary Outcome Measures

Global Clinical Impressions
Outcome Questionnaire --- a Self-report Questionnaire
Medical Outcomes Study 36-Item Short Form Health Survey (SF-36)

Full Information

First Posted
April 28, 2005
Last Updated
September 11, 2012
Sponsor
University of Calgary
Collaborators
Alberta Innovation and Science
search

1. Study Identification

Unique Protocol Identification Number
NCT00109577
Brief Title
Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder
Official Title
Randomized Placebo-controlled Phase II Trial of MCN36 in Adults With Bipolar Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Terminated
Why Stopped
Unable to recruit large enough sample; large expectancy effects but no adverse events
Study Start Date
April 2005 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Calgary
Collaborators
Alberta Innovation and Science

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the trial was to determine whether a 36-ingredient micronutrient supplement (primarily vitamins and minerals) is beneficial for the treatment of bipolar disorder, when studied under randomized and fully blinded conditions and compared to a placebo. The supplement is referred to as MCN36, because it contains 36 nutrients. Based on the preliminary research on this supplement, it is hypothesized that patients who take MCN36 for 8 weeks will experience improved mood stability relative to those who take the placebo. All participants must live EITHER in the vicinity of Calgary, Alberta, Canada, OR in the area of San Diego, California.
Detailed Description
This RCT (randomized clinical trial) compared MCN36 to placebo in patients randomized to receive one or the other for 8 weeks. Close medical supervision was provided with weekly appointments. At the end of the 8 weeks, all participants were offered the opportunity of entering an 8-week open-label extension. The efficacy objective of this study was to assess the efficacy of MCN36 compared with placebo in otherwise medication-free adults with bipolar disorder I and II, in improving overall symptomatology at the end of 8 weeks of therapy as assessed under randomized and fully blinded conditions as measured by the clinician using the Overall Bipolarity Index (OBI) (primary outcome measure). as measured by the clinician using the Clinical Global Impressions for Bipolar Disorder (CGI-BP) for Severity. as measured by self-report recorded on the Outcome Questionnaire (OQ). in terms of rate of response, with response defined as a reduction of 50% or more in either the depression or the mood elevation component of the OBI. in terms of functional states and health-related quality of life as measured by The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). The safety-related objective was to assess the safety of MCN36 compared with placebo in terms of laboratory analyses treatment-emergent adverse events, which will be solicited at each appointment using the Adverse Event Log. Participants had two appointments for screening and confirming suitability for the trial. Between those two appointments, they provided a blood sample, and met with a research nurse. They also kept a 7-day food record of their food intake prior to the second appointment. If suitability was confirmed at the second visit, they entered the randomized phase.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder
Keywords
bipolar disorder, mood disorders, manic depression, nutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Placebo comparator, 6 placebo capsules three times a day
Arm Title
1
Arm Type
Experimental
Arm Description
nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.
Intervention Type
Drug
Intervention Name(s)
MCN36 (nutritional supplement)
Intervention Description
nutritional supplement
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
nutritional supplement
Primary Outcome Measure Information:
Title
Mood as Evaluated by the Overall Bipolarity Index (Composite of the Hamilton Depression Scale and the Young Mania Rating Scale)
Description
Change in mood from baseline to final visit, as evaluated by the Overall Bipolarity Index (composite of the Hamilton Depression Scale and the Young Mania Rating Scale); minimum possible score is 0 and maximum possible score is 103; higher scores mean worse symptomatology
Time Frame
Baseline to 8 weeks
Secondary Outcome Measure Information:
Title
Global Clinical Impressions
Time Frame
Baseline to 8 weeks
Title
Outcome Questionnaire --- a Self-report Questionnaire
Time Frame
Baseline to 8 weeks
Title
Medical Outcomes Study 36-Item Short Form Health Survey (SF-36)
Time Frame
Baseline to 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must meet the criteria for bipolar disorder I or II as defined in DSM-IV-TR based on clinical assessment and confirmed by structured diagnostic interview (SCID-P). Must be symptomatic on the Hamilton Depression Scale and the Young Mania Rating Scale Must be free of medications or herbal/nutritional supplements with primarily central nervous system activity Must be able to eat at least a snack three times per day, so that the capsules will not be ingested on an empty stomach Exclusion Criteria: Current or lifetime diagnosis of any of the following according to DSM-IV-TR criteria: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Psychotic Disorder Not Otherwise Specified, Delirium of any type, Dementia of any type, Amnestic Disorder, unless there is substantive reason to believe the patient was misdiagnosed. Alcohol dependence or abuse in the previous six months. Dependence or abuse of substances other than alcohol in the previous two years. Any Psychotic Disorder due to a General Medical Condition in the previous two years Hospitalization for treatment of a mental disorder within the previous 6 months. Current use of any other medication or herbal/nutritional supplement with primarily central nervous system activity. Neurological disorder involving brain or other central function. Severe headaches of any type (including migraine) within the previous 3 months. Unstable illnesses either with active significant symptoms or requiring medication changes within the previous 4 months. Abnormal laboratory values detected at screening, in particular an ALT or AST greater than 2 times the upper limit of normal, or creatinine greater than 1.75 times the upper limit of normal. Uncorrected or unstable hypothyroidism or hyperthyroidism in the previous 12 months. Medically diagnosed Irritable Bowel Syndrome, or any other chronic gastrointestinal problem, within the previous 3 years. Current or lifetime metabolic disorder or problem, such as phenylketonuria or Wilson's disease. A course of treatment with electroconvulsive therapy (ECT) within the previous 12 months, or a lifetime history of four or more courses of ECT. Current bacterial, viral, fungal, parasite or other infection. Women who are pregnant or breast-feeding; women of childbearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bonnie J Kaplan, PhD
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dr Estelle Goldstein
City
San Diego
State/Province
California
ZIP/Postal Code
92116
Country
United States
Facility Name
University of Calgary Faculty of Medicine
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N1
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
11780873
Citation
Kaplan BJ, Simpson JS, Ferre RC, Gorman CP, McMullen DM, Crawford SG. Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. J Clin Psychiatry. 2001 Dec;62(12):936-44. doi: 10.4088/jcp.v62n1204.
Results Reference
background
PubMed Identifier
15142398
Citation
Kaplan BJ, Fisher JE, Crawford SG, Field CJ, Kolb B. Improved mood and behavior during treatment with a mineral-vitamin supplement: an open-label case series of children. J Child Adolesc Psychopharmacol. 2004 Spring;14(1):115-22. doi: 10.1089/104454604773840553.
Results Reference
background
PubMed Identifier
12427294
Citation
Kaplan BJ, Crawford SG, Gardner B, Farrelly G. Treatment of mood lability and explosive rage with minerals and vitamins: two case studies in children. J Child Adolesc Psychopharmacol. 2002 Fall;12(3):205-19. doi: 10.1089/104454602760386897.
Results Reference
background
PubMed Identifier
11780872
Citation
Popper CW. Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? J Clin Psychiatry. 2001 Dec;62(12):933-5. doi: 10.4088/jcp.v62n1203. No abstract available.
Results Reference
background
PubMed Identifier
12716280
Citation
Simmons M. Nutritional approach to bipolar disorder. J Clin Psychiatry. 2003 Mar;64(3):338; author reply 338-9. doi: 10.4088/jcp.v64n0317d. No abstract available.
Results Reference
background
PubMed Identifier
17723028
Citation
Kaplan BJ, Crawford SG, Field CJ, Simpson JS. Vitamins, minerals, and mood. Psychol Bull. 2007 Sep;133(5):747-60. doi: 10.1037/0033-2909.133.5.747.
Results Reference
background

Learn more about this trial

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

We'll reach out to this number within 24 hrs